Zeria Pharmaceuticals launches Hanp Injection

28 May 1995

- Zeria Pharmaceutical has launched Hanp Inj (carperitide) in Japan for the management of patients with acute heart failure. The drug is said to be the first recombinant alpha-type human atrial sodium diuretic polypeptide preparation to reach the market, according to Pharma Japan. Zeria is targeting first-year sales of 360 million yen ($4.3 million). The drug reportedly has arteriovenous vasodilating and diuretic effects, improves preload and afterload, does not cause an increase in heart rate or myocardial oxygen consumption and has a low incidence of side effects (5.1%).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight